DOI QR코드

DOI QR Code

Serum Concentration of Nitrotyrosine as Indicator of Disease Progress in Dogs with Myxomatous Mitral Valve Disease

  • Bang, Ju-Hwan (College of Veterinary Medicine, Chungnam National University) ;
  • Park, Jun-Seok (College of Veterinary Medicine, Chungnam National University) ;
  • Seo, Kyoung-Won (College of Veterinary Medicine, Chungnam National University) ;
  • Song, Kun-Ho (College of Veterinary Medicine, Chungnam National University)
  • 투고 : 2019.01.09
  • 심사 : 2019.03.18
  • 발행 : 2019.04.30

초록

Nitrotyrosine was found to be dependent on the severity of myxomatous mitral valve disease (MMVD). However, a correlation of serum nitrotyrosine concentration in dogs with MMVD and the progression of the disease has not been investigated. This study compared changes in serum nitrotyrosine concentration with the progression of MMVD. Nine client-owned dogs were recruited for the study. Dogs were classified by measuring the amount of regurgitation using echocardiography into mild, moderate, or severe MMVD groups. Serum nitrotyrosine concentration was measured by an enzyme-linked immunosorbent assay test. Serum nitrotyrosine concentration was significantly higher at 180 days than at 0 day (P < 0.05). However, serum nitrotyrosine concentration at 360 days was lower than that at 180 days (P < 0.05). Serum nitrotyrosine concentration at 540 days was lower than at 180 days (P < 0.05). There was no correlation between serum nitrotyrosine and left atrial to aortic root diameter ratio (LA/Ao ratio) (n = 33, $R^2=0.003$, P = 0.759). Also, there was no correlation between serum nitrotyrosine and vertebral heart score (VHS) (n = 33, $R^2=0.026$, P = 0.368) and left ventricular end-diastolic diameter, normalized for body weight by the formula (LVEDDN) (n = 33, $R^2=0.053$, P = 0.196). The results of the study suggest that the progression of MMVD is correlated with changes in serum nitrotyrosine concentration, which shows potential for use as a cardiac biomarker which can be used to analyze the progression of disease in MMVD.

키워드

참고문헌

  1. Atkins C, Bonagura J, Ettinger S, Fox P, Gordon S, Haggstrom J, Hamlin R, Keene B, Luis-Fuentes V, Stepien R. Gudelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med 2009; 23: 1142-1150. https://doi.org/10.1111/j.1939-1676.2009.0392.x
  2. Balligand JL, Ungureanu-Longrois D, Simmons WW, Pimental D, Malinski TA, Kapturczak M, Taha Z, Lowenstein CJ, Davidoff AJ, Kelly RA. Cytokine-inducible nitric oxide synthase (iNOS) expression in cardiac myocytes. J Biol Chem 1994; 269: 25780-27588.
  3. Belardinelli, R. Endothelial dysfunction in chronic heart failure: clinical implications and therapeutic options. Int J Cardiol 2001; 81: 1-8. https://doi.org/10.1016/S0167-5273(01)00525-3
  4. Boswood A. Biomarkers in cardiovascular disease : beyond natriuretic peptides. J Vet Cardiol 2009; 11: S23-32. https://doi.org/10.1016/j.jvc.2009.01.003
  5. Chen YJ, Traverse JH, Du R, Hou MX, Bache RJ. Nitric oxide modulates myocardial oxygen consumption in the failing heart. Circulation 2002; 106: 273-279. https://doi.org/10.1161/01.CIR.0000021120.90970.B9
  6. de Belder AJ, Why HJF, Radomski MW, Richardson PJ, Bucknall CA, Martin JF, Radomski MW, Salas E, Moncada S. Nitric oxide synthase activities in human myocardium. Lancet 1993; 341: 84-85. https://doi.org/10.1016/0140-6736(93)92559-C
  7. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992; 257: 387-389. https://doi.org/10.1126/science.1631560
  8. Funakoshi H, Kubota T, Machida Y, Kawamura N, Feldman AM, Tsutsui H, Shimokawa H, Takeshita A. Involvement of inducible nitric oxide synthase in cardiac dysfunction with tumor necrosis factor-a. Am J Physiol Heart Circ Physiol 2002; 282: 2159-2166. https://doi.org/10.1152/ajpheart.00872.2001
  9. Ghiadoni L, Magagna A, Versari D, Kardasz I, Huang Y, Taddei S, Salvetti A. Different effect of antihypertensive drugs on conduit artery endothelial function. AHA Hypertension 2003; 41: 1281-1286. https://doi.org/10.1161/01.HYP.0000070956.57418.22
  10. Kim JS, Park JS, Park HJ, Seo KY, Song KH. Serum nitrotyrosine conentration in dogs with myxomatous mitral valve disease. Korean J Vet Res 2017; 57: 17-21. https://doi.org/10.14405/kjvr.2017.57.1.17
  11. Lowenstein CJ, Dinerman JL, Snyder SH. Nitric oxide: A physiologic messenger. Ann Intern Med 1994; 120: 227-237. https://doi.org/10.7326/0003-4819-120-3-199402010-00009
  12. Mow T, Pedersen HD. Increased endothelin-receptor density in myxomatous canine mitral valve leaflets. J Cardiovasc Pharmacol 1999; 34: 254-260. https://doi.org/10.1097/00005344-199908000-00011
  13. Nakazawa H, Fukuyama N, Takizawa S, Tsuji C, Yoshitake M, Ishida H. Nitrotyrosine formation and its role in various pathological conditions. Free Radic Res 2000; 33: 771-784. https://doi.org/10.1080/10715760000301291
  14. Nelson RW and Couto CG. Acquired valvular and endocardial disease. In: Small Animal Internal Medicine, 5th ed. St. Louis : Elsevier. 2013: 115-120.
  15. Olsen LH, Mortensen K, Martinussen T, Larsson LI, Baandrup U, Pedersen HD. Increased NADPH-Diaphorase activity in canine myxomatous mitral valve leaflets. J Comp Path 2003; 129: 120-130. https://doi.org/10.1016/S0021-9975(03)00019-7
  16. Pedersen HD, Schutt T, Sondergaard R, Qvortrup K, Olsen LH, Kristensen AT. Decreased plasma concentration of nitric oxide metabolites in dogs with untreated mitral regurgitation. J Vet Intern Med 2003; 17: 178-184. https://doi.org/10.1111/j.1939-1676.2003.tb02431.x
  17. Ruaux C, Scollan K, Suchodolski JS, Steiner JM, Sisson DD. Biologic variability in NT-proBNP and cardiac troponin-I in healthy dogs dogs with mitral valve degeneration. Vet Clin Pathol 2015; 44: 420-430. https://doi.org/10.1111/vcp.12268
  18. Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, Mann DL. Tumor necrosis factor a and tumor necrosis factor receptors in the failing human heart. Circulation 1996; 93: 704-711. https://doi.org/10.1161/01.CIR.93.4.704
  19. Feng Q, Lu X, Jones DL, Shen J, Arnold JMO. Increased inducible nitric oxide synthase expression contributes to myocardial dysfunction and higher mortality after myocardial infarction in mice. Circulation 2001; 104: 700-704. https://doi.org/10.1161/hc3201.092284